433 related articles for article (PubMed ID: 21992861)
1. Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.
Merchant R; Ahmed J; Krishnan P; Jankharia B
Indian Pediatr; 2012 Apr; 49(4):281-5. PubMed ID: 21992861
[TBL] [Abstract][Full Text] [Related]
2. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
Vlachaki E; Agapidou A; Spanos G; Klonizakis P; Vetsiou E; Mavroudi M; Boura P
Hemoglobin; 2015; 39(5):299-304. PubMed ID: 26177199
[TBL] [Abstract][Full Text] [Related]
3. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
4. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
Gao HY; Li Q; Chen JJ; Chen GF; Li CG
Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul; 13(7):531-4. PubMed ID: 21752315
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.
Pennell DJ; Porter JB; Cappellini MD; El-Beshlawy A; Chan LL; Aydinok Y; Elalfy MS; Sutcharitchan P; Li CK; Ibrahim H; Viprakasit V; Kattamis A; Smith G; Habr D; Domokos G; Roubert B; Taher A
Blood; 2010 Mar; 115(12):2364-71. PubMed ID: 19996412
[TBL] [Abstract][Full Text] [Related]
6. A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients.
Cassinerio E; Roghi A; Orofino N; Pedrotti P; Zanaboni L; Poggiali E; Giuditta M; Consonni D; Cappellini MD
Ann Hematol; 2015 Jun; 94(6):939-45. PubMed ID: 25563596
[TBL] [Abstract][Full Text] [Related]
7. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
[TBL] [Abstract][Full Text] [Related]
9. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload.
Pennell DJ; Porter JB; Cappellini MD; Chan LL; El-Beshlawy A; Aydinok Y; Ibrahim H; Li CK; Viprakasit V; Elalfy MS; Kattamis A; Smith G; Habr D; Domokos G; Roubert B; Taher A
Haematologica; 2011 Jan; 96(1):48-54. PubMed ID: 21071497
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience.
Karakas Z; Yilmaz Y; Bayramoglu Z; Karaman S; Aydogdu S; Karagenc AO; Tugcu D; Dursun M
Radiol Med; 2018 Aug; 123(8):572-576. PubMed ID: 29663188
[TBL] [Abstract][Full Text] [Related]
11. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores.
Wood JC; Kang BP; Thompson A; Giardina P; Harmatz P; Glynos T; Paley C; Coates TD
Blood; 2010 Jul; 116(4):537-43. PubMed ID: 20421452
[TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.
Gomber S; Jain P; Sharma S; Narang M
Indian Pediatr; 2016 Mar; 53(3):207-10. PubMed ID: 27029681
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
Xia S; Zhang W; Huang L; Jiang H
PLoS One; 2013; 8(12):e82662. PubMed ID: 24376563
[TBL] [Abstract][Full Text] [Related]
14. Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI.
Ruffo GB; Borsellino Z; Cuccia L; Marocco MR; Gagliardotto F; Tarantino R
Clin Drug Investig; 2010; 30(4):267-73. PubMed ID: 20225910
[TBL] [Abstract][Full Text] [Related]
15. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).
Pennell DJ; Porter JB; Piga A; Lai Y; El-Beshlawy A; Belhoul KM; Elalfy M; Yesilipek A; Kilinç Y; Lawniczek T; Habr D; Weisskopf M; Zhang Y; Aydinok Y;
Blood; 2014 Mar; 123(10):1447-54. PubMed ID: 24385534
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
[TBL] [Abstract][Full Text] [Related]
17. Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies.
Fragomeno C; Roccabruna E; D'Ascola DG
Blood Cells Mol Dis; 2015 Dec; 55(4):382-6. PubMed ID: 26460263
[TBL] [Abstract][Full Text] [Related]
18. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).
Ho PJ; Tay L; Teo J; Marlton P; Grigg A; St Pierre T; Brown G; Badcock CA; Traficante R; Gervasio OL; Bowden DK
Eur J Haematol; 2017 Feb; 98(2):97-105. PubMed ID: 27537786
[TBL] [Abstract][Full Text] [Related]
19. Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.
Pennell DJ; Porter JB; Piga A; Lai YR; El-Beshlawy A; Elalfy M; Yesilipek A; Kilinç Y; Habr D; Musallam KM; Shen J; Aydinok Y;
Am J Hematol; 2015 Feb; 90(2):91-6. PubMed ID: 25345697
[TBL] [Abstract][Full Text] [Related]
20. Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.
Pathare A; Taher A; Daar S
Ann Hematol; 2010 Apr; 89(4):405-9. PubMed ID: 19798501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]